| |  Online-Ressource |
|---|
| Verfasst von: | König, Laila [VerfasserIn]  |
|---|
| | Dreyling, Martin [VerfasserIn] |
|---|
| | Dürig, Jan [VerfasserIn] |
|---|
| | Engelhardt-Schagen, Marianne [VerfasserIn] |
|---|
| | Hohloch, Karin [VerfasserIn] |
|---|
| | Viardot, Andreas [VerfasserIn] |
|---|
| | Witzens-Harig, Mathias [VerfasserIn] |
|---|
| | Kieser, Meinhard [VerfasserIn] |
|---|
| | Klapper, Wolfram [VerfasserIn] |
|---|
| | Pott, Christiane [VerfasserIn] |
|---|
| | Herfarth, Klaus [VerfasserIn] |
|---|
| Titel: | Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy) |
|---|
| Titelzusatz: | a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial |
|---|
| Verf.angabe: | Laila König, Martin Dreyling, Jan Dürig, Marianne Engelhard, Karin Hohloch, Andreas Viardot, Mathias Witzens-Harig, Meinhard Kieser, Wolfram Klapper, Christiane Pott, and Klaus Herfarth |
|---|
| E-Jahr: | 2019 |
|---|
| Jahr: | 30 August 2019 |
|---|
| Umfang: | 8 S. |
|---|
| Fussnoten: | Gesehen am 15.04.2020 |
|---|
| Titel Quelle: | Enthalten in: Trials |
|---|
| Ort Quelle: | London : BioMed Central, 2000 |
|---|
| Jahr Quelle: | 2019 |
|---|
| Band/Heft Quelle: | 20(2019), Artikel-ID 544, Seite 1-8 |
|---|
| ISSN Quelle: | 1468-6694 |
|---|
| | 1745-6215 |
|---|
| Abstract: | Large field irradiation had been standard for early-stage follicular lymphoma (FL) for a long time. Although involved field radiotherapy (IF-RT) was recently favored because of the toxicity of large field irradiation, smaller irradiation fields have been accompanied with an increased risk of out-of-field recurrence. The MIR (MabThera® and Involved field Radiation) trial has shown that the combination of IF-RT at a dose of 30-40 Gy with the anti-CD20 antibody rituximab has led to similar efficacy compared with large field irradiation but with markedly reduced side effects. Immune modulating radiation therapy alone using low-dose radiotherapy (LDRT) of 2 × 2 Gy has been shown to be effective in FL. The GAZAI (GAZyvaro and response Adapted Involved-site Radiotherapy) trial aims to prove the efficacy of LDRT in combination with a novel anti-CD20 therapy. |
|---|
| DOI: | doi:10.1186/s13063-019-3614-y |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1186/s13063-019-3614-y |
|---|
| | DOI: https://doi.org/10.1186/s13063-019-3614-y |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1694553868 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy) / König, Laila [VerfasserIn]; 30 August 2019 (Online-Ressource)
